Skip to main content
TipRanks
Go Ultimate75% OFF

Natera (45E) Stock Price & Analysis

4 Followers

45E Stock Chart & Stats

€251.70-€22.00(-8.04%)
At close: 5:30 PM GMT+1
€250€300€350Aug 24Sep 7Sep 21Oct 5Oct 21Nov 2Nov 16
Day’s Range
EUR 251.70 - EUR 264.00
52-Week Range
EUR 158.00 - EUR 391.30
Previous Close
EUR 273.70
Volume
N/A
Average Volume (3M)
91
Market Cap
EUR 38.31B
Enterprise Value
EUR 58.69B
Total Cash (Recent Filing)
EUR 1.10B
Total Debt (Recent Filing)
EUR 238.84M
Price to Earnings (P/E)
―
Beta
0.32
Next Earnings
Mar 04, 2027 (Est.)
Next Dividend Ex-Date
N/A
Dividend Yield
N/A

Bulls Say, Bears Say

Bulls Say

Rapid Revenue And Testing Growth

Rapid growth in both testing volume and revenue indicates broadening clinical adoption across Natera’s platforms. Higher utilization can strengthen laboratory leverage, deepen clinician relationships, and provide a durable foundation for continued expansion across women’s health, organ health, and oncology.

Improving Margins And Cash Generation

Gross-margin expansion alongside renewed cash generation suggests improving economics as testing scales, pricing improves, and laboratory capacity is used more efficiently. This strengthens internal funding for product development and commercialization while reducing reliance on external capital over the coming quarters.

Expanding Oncology And Reimbursement Reach

Accelerating MRD adoption and broader Medicare coverage expand the addressable reimbursed market for Natera’s recurring monitoring tests. More covered indications can support repeat utilization, improve revenue visibility, and reinforce Signatera’s role in longitudinal cancer and transplant care.

Bears Say

Profitability Remains Negative

Despite strong revenue growth and narrower losses, Natera has not yet converted scale into sustainable operating profitability. Continued negative operating earnings leave less cushion for execution setbacks and make the business dependent on maintaining growth, margin progress, and disciplined investment.

Elevated Investment And Cost Pressure

Higher spending on trials, commercial initiatives, pharma services, and early detection can delay operating leverage even as revenue expands. Added cost of goods from newer products further pressures near-term margins, requiring successful scaling and cost-reduction work over the next 18 to 24 months.

Reimbursement Execution Uncertainty

Future growth depends partly on reimbursement decisions that remain outside Natera’s direct control. Delays or unfavorable outcomes for MolDX submissions could slow adoption and collections, while unresolved Japan pricing and reimbursement postpone the expected benefit from international expansion.

Natera News

45E FAQ

What was Natera’s price range in the past 12 months?
Natera lowest stock price was €158.00 and its highest was €391.30 in the past 12 months.
What is Natera’s market cap?
Natera’s market cap is €38.31B.
When is Natera’s upcoming earnings report date?
Natera’s next earnings report is estimated for Mar 04, 2027 (not yet confirmed), which is in 103 days.
How were Natera’s earnings last quarter?
Natera released its earnings results on Nov 05, 2026. The company reported -€0.382 earnings per share for the quarter, missing the consensus estimate of -€0.256 by -€0.126.
Is Natera overvalued?
According to Wall Street analysts Natera’s price is currently Undervalued.
Does Natera pay dividends?
Natera does not currently pay dividends.
What is Natera’s EPS estimate?
Natera’s EPS estimate is -0.15.
How many shares outstanding does Natera have?
Natera has 145,004,520 shares outstanding.
What happened to Natera’s price movement after its last earnings report?
Natera reported an EPS of -€0.382 in its last earnings report, missing expectations of -€0.256. Following the earnings report the stock price went down -14.5%.
Which hedge fund is a major shareholder of Natera?
Hedge funds hold Natera shares: the largest hedge-fund position in Natera is 1,972,589,981 shares, and hedge funds decreased their holdings by 244.6K shares last quarter.
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology